{"nctId":"NCT00464087","briefTitle":"Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI","startDateStruct":{"date":"2007-06"},"conditions":["Acute Coronary Syndromes"],"count":100,"armGroups":[{"label":"Heparin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin"]},{"label":"Bivalirudin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin"]}],"interventions":[{"name":"Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1\\. The patient is, male or female, \\> 18 years of age; 2. The patient presents with coronary syndrome, unstable angina or non ST segment elevated myocardial infarction (NSTEMI) defined as at least one of the following criteria:\n\n* Elevated creatine kinase MB or Troponin I or T (above ULN)\n* ECG changes indicative of ischemia 3. The patient is scheduled for angiography, with possible angioplasty, evaluation of their coronary disease; 4. The patient is able and willing to conform to the requirements of the study and voluntarily signs an Informed Consent.\n\n  1. ST elevated myocardial infarction within the preceding 48 hours;\n  2. Patient weighs more than 400 lbs (181.2 kg) or less than 110 lbs (50 kg);\n  3. Patients presenting on or received bivalirudin, GP IIb/IIIa inhibitors or low-molecular weight heparin within the preceding 24 hours;\n  4. Patients that received unfractionated heparin less than or equal to 90 minutes prior to fondaparinux administration.\n  5. Patients with known conditions of bleeding diathesis or actively bleeding within the previous 6 months (GI bleed etc.);\n  6. Known diagnosis of acute bacterial endocarditis;\n  7. Patients with cardiogenic shock or required intra-aortic balloon pump (IABP)\n  8. If patient is on warfarin (Coumadin) therapy;\n  9. Patients who had a major or minor stroke (CVA or TIA) or major surgery within the past 6 months;\n  10. Known impaired renal function (creatinine ≥ 3.0 mg/dL (265.2 μmol/L),) status post renal transplant, patients on chronic dialysis or creatinine clearance ≤ 30 ml/min;\n  11. A platelet count of less than 100,000 cells/mm3;\n  12. Known allergies to fondaparinux, aspirin, clopidogrel bisulfate (PlavixR), ticlopidine (TiclidR), heparin, bivalirudin, or contrast that cannot be medically managed;\n  13. Prior angioplasty within the previous 30 days;\n  14. Contraindication to low-molecular weight heparin, unfractionated heparin or bivalirudin;\n  15. Pregnant or lactating women;\n  16. Any significant medical condition, which in the investigator's opinion, may interfere with the patient's optimal participation in the study;\n  17. Currently participating in an investigational drug or another device study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Primary Endpoint Will be in Hospital Major Bleed as Defined by the Study Protocol, Assessed at Three Time Points: After Study Drug Administration, But Prior to Randomization;After Randomization During PCI; and After PCI, Prior to Discharge","description":"Characterized as Fatal bleed, Major bleed (SWITCH III criteria) or major bleed (OASIS criteria)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary in Hospital Endpoint Will be In-hospital Death (Non-hemorrhagic Related), Vascular Access Site Complications, Myocardial Infarction, Need for Repeat Revascularization, Procedural Complication and Catheter Thrombosis","description":"Characterized as death, access site complication, access site thrombus, hematoma, myocardial infarction, repeat vascularization, dissection, stent thrombosis, catheter thrombosis","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"PRIMARY","title":"The Primary Endpoint Will be in Hospital Major Bleed as Defined by the Study Protocol, Assessed at Three Time Points: After Study Drug Administration, But Prior to Randomization;After Randomization During PCI; and After PCI, Prior to Discharge","description":"Categorized as Fatal bleed, major bleed (SWITCH III criteria) or major bleed (OASIS criteria)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"The Primary Endpoint Will be in Hospital Major Bleed as Defined by the Study Protocol, Assessed at Three Time Points: After Study Drug Administration, But Prior to Randomization;After Randomization During PCI; and After PCI, Prior to Discharge","description":"Characterized as fatal bleed, major bleed (SWITCH III criteria) or major bleed (OASIS criteria)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":49},"commonTop":["Access Site Complication","Dissection","Ventricular fibrillation","Repeat revascularization"]}}}